Metastatic Solid Tumors
70
17
23
24
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
13 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
7 terminated out of 70 trials
77.4%
-9.2% vs benchmark
1%
1 trials in Phase 3/4
54%
13 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 24 completed trials
Clinical Trials (70)
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
A Study of DS3610a in Participants With Advanced Solid Tumor
A Study of IOV-5001 in Adults With Advanced Solid Tumors
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors